Medical Implants in the US, 6th Edition
The study addresses the following questions and more:
- What types of medical implants will generate the fastest unit and revenue growth over the next five years?
- How will ongoing safety controversies, elevated patient complication risks, and recurring product recalls impact growth opportunities for various widely used medical implants?
- Will advances in deep brain stimulation (DBS) and vagus nerve stimulation (VNS) technologies significantly improve therapeutic outcomes and quality of life criteria for patients afflicted with epilepsy, major depression, Parkinson's disease, and other widely prevalent neurological disorders?
Read the full report: http://www.reportlinker.com/p04708289-summary/view-report.html
Description
Medical implant sales in the US are driven by a growing prevalence of chronic orthopedic, cardiovascular, neuro- logical, ophthalmic, hearing loss, and various other conditions that are not responsive to pharmaceutical or less invasive surgical therapies.
Lifestyles affect sales growth
A rising incidence of injuries attributable to the expansion of sports activities, the increasing adoption of exercise- active lifestyles, and the high vulnerability of elderly individuals to falls and other accidents will broaden revenue opportunities for bone substitutes, tissue implants, and internal fixation devices employed in spinal fusion, trauma treatment, and fracture repair. Demand for the orthobiologic hyaluronic acid will advance at a fast pace based on widening use in osteoarthritis therapy and cosmetic surgery. Lastly, demand for dental implants will see sizeable gains as the prevalence of serious tooth and gum diseases in the aging population rises and the avail- ability of affordable dental insurance improves.
Orthopedics to remain top-selling group
Orthopedic products will remain the top-selling group of medical implants, with total demand advancing over five percent annually. A combination of demographic, lifestyle, and epidemiological trends will promote growth. The aging of the population will boost the prevalence of degenerative musculoskeletal conditions often requiring reconstructive joint replacement and/or spinal surgery.
Cardiac implants will generate growth
The second-largest selling group of medical implants treats or manages various types of heart disease. Revenues generated by cardiac implants will be spread fairly evenly among three major product lines -- pacing devices, cardiac stents and related implants, and structural cardiac implants. Structural cardiac implants will generate the fastest growth in demand value due to upward trends in the prevalence of vavular heart disease and the increasing use of high value-added tissue-based replacement valves. By contrast, sales of pacing devices will grow slowly as advances in pharmaceuticals and surgical therapies eliminate the need for implants in some patients afflicted with heart rhythm disorders. Lastly, a heightened level of coronary and peripheral artery diseases will boost the market for cardiac stents and related products.
Study coverage
Medical Implants in the US (Orthopedic, Cardiac & Other), 6th Edition presents historical demand data (2005, 2010 and 2015) plus forecasts (2020 and 2025) for orthopedic (e.g., reconstructive joint replacements, spinal implants, orthobiologics), cardiac (e.g., stents and related implants, pacing devices) and other medical implants (e.g., gastroenterologicals, urologicals, cosmetics).
Read the full report: http://www.reportlinker.com/p04708289-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medical-implants-in-the-us-6th-edition-300412216.html
SOURCE Reportlinker



A break amid strong water year in the North State
EDITORIAL: Thursday’s Affordable Care Act gets mixed grades, but cost remains No. 1 issue
Advisor News
- How smart investments prepare clients for inflation
- Amid slew of corporate tax ideas, Newsom chose one likely to hit people’s premiums
- The biggest risk to your clients’ financial plans isn’t market volatility
- Initiative looks at how caregiving impacts workplace benefits
- Will rising retirement needs spark an annuity boom?
More Advisor NewsAnnuity News
- Globe Life Inc. (NYSE: GL) Records 52-Week High Thursday Morning
- Fortitude Re Completes $500 Million FABN Issuance
- Reframing retirement income for greater certainty
- Jackson Introduces Dow Jones Industrial Average Index Option, Flexible Premiums, Six-Year Rate Guarantee in Latest Registered Index-Linked Annuity Launch
- Senior Market Sales® Fortifies Annuity Reach With Acquisition of Retirement Planning Firm Stratton & Company
More Annuity NewsHealth/Employee Benefits News
- Report Summarizes Geriatrics and Gerontology Study Findings from National Center for Geriatrics and Gerontology (Multi-domain Functional Dispersion and Disability-Free Survival among Community-Dwelling Older Adults: An Exploratory Study): Aging Research – Geriatrics and Gerontology
- Findings from Brown University in Managed Care Reported (Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs): Managed Care
- Findings from Arnot Ogden Medical Center Broaden Understanding of Diabetic Ketoacidosis (Diabetic Ketoacidosis From Health Insurance-Requested Non-medical Switching): Nutritional and Metabolic Diseases and Conditions – Diabetic Ketoacidosis
- Mark Farrah Associates Analyzed the 2025 Medicare Supplement Market
- 3 Million Seniors Lost Their Medicare Advantage Plan in 2026: 7 Moves to Make Before Your Coverage Lapses
More Health/Employee Benefits NewsLife Insurance News
- Lobbyist argues Iowa insurance regulator gives too much voice to Wall Street
- Appeals court rejects investor payouts in latest decision against STOLI
- Why premium-financed IUL is failing
- AM Best Affirms Issue Credit Ratings of Weston2038 LLC’s Credit-Linked Notes
- Globe Life Inc. (NYSE: GL) Records 52-Week High Thursday Morning
More Life Insurance News